Healthcare / Drug Manufacturers - Specialty & GenericBSE
$237.00
-1.00 (-0.42%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 35% · confianza 10%
FCF escenarios
weak_data · normalized FCF $-15.4M · quality 19.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
47/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.5B
P/E
53.9x
↑EV/EBITDA
20.0x
↑ROE
29.1%
↑Gross Margin
24.7%
↓Debt/Equity
2.90
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+49.2%
FCF CAGR
—
FCF margin
-1.6%
FCF / Net income
-0.29x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $972.0M · net income $53.5M · FCF $-15.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $972.0M | $972.0M | $793.4M | $661.0M | $292.5M |
| Net Income | $53.5M | $53.5M | $40.7M | $6.7M | $2.5M |
| EBITDA | $151.2M | $151.2M | $117.8M | $72.7M | $58.6M |
| EPS | 5.09 | 5.09 | 3.87 | 0.63 | 0.24 |
| Gross Margin | 24.7% | 24.7% | 23.5% | 17.0% | 28.6% |
| Operating Margin | 11.0% | 11.0% | 10.6% | 4.9% | 7.2% |
| Net Margin | 5.5% | 5.5% | 5.1% | 1.0% | 0.9% |
| Balance Sheet | |||||
| Debt/Equity | 2.90 | 2.90 | 3.54 | 4.41 | 3.94 |
| Current Ratio | 1.96 | 1.96 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-15.4M | $-15.4M | $4.0M | $-41.7M | $-82.6M |
| Returns | |||||
| ROE | 29.1% | 29.1% | 34.0% | 8.2% | 3.3% |
| Valuation | |||||
| P/E | 53.86 | 53.86 | — | — | — |
| EV/EBITDA | 20.00 | 20.00 | — | — | — |
| P/B | 13.53 | 13.53 | — | — | — |
| Growth & Yield | |||||
| Revenue Growth | 22.5% | 22.5% | 20.0% | 126.0% | — |
| EPS Growth | 31.5% | 31.5% | 511.9% | 167.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
60.5%
EPS terminal req.
$21.03
Spread vs growth
-29.0%
5Y implied EPS CAGR
38.0%
EPS terminal req.
$25.45
Spread vs growth
-6.5%
10Y implied EPS CAGR
23.2%
EPS terminal req.
$40.98
Spread vs growth
8.3%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+74.7%
Start / end P/E
35.0x → 46.6x
EPS bridge
3.87 → 5.09
Residual
+10.4%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.